1. DCC-2618, a pan KIT and PDGFR switch control inhibitor, achieves proof-of-concept in a first-in-human study. (December 2016) Authors: Janku, F.; George, S.; Razak, A.; Gordon, M.; Brooks, D.; Flynn, D.G.; Kaufman, M.; Pitman, J.; Smith, B.; Somaiah, N.; Gerstenberger, E.; Westwood, D.; Rosen, O. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S4 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Detection of SARS-CoV-2 within the healthcare environment: a multi-centre study conducted during the first wave of the COVID-19 outbreak in England. (February 2021) Authors: Moore, G.; Rickard, H.; Stevenson, D.; Aranega-Bou, P.; Pitman, J.; Crook, A.; Davies, K.; Spencer, A.; Burton, C.; Easterbrook, L.; Love, H.E.; Summers, S.; Welch, S.R.; Wand, N.; Thompson, K-A.; Pottage, T.; Richards, K.S.; Dunning, J.; Bennett, A. Journal: Journal of hospital infection Issue: Volume 108(2021) Page Start: 189 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Rationale for a reverse tapered body shift implant for immediate placement. Issue 12 (December 2020) Authors: Christiaens, V.; Pitman, J.; Glibert, M.; Hommez, G.; Atashkadeh, M.; De Bruyn, H. Journal: International journal of oral & maxillofacial surgery Issue: Volume 49:Issue 12(2020:Dec.) Page Start: 1630 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. The ULK1 inhibitor ENV-201 impairs tumor growth in KRAS-driven flank xenografts as a single agent and in combination with the KRAS inhibitor adagrasib. (October 2022) Authors: Pitman, J.; Dellamary, L.; Kc, S.; de los Rios, M.; Hood, J. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S34 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗